Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
Tweet Send to a Friend
Goldman Sachs maintained a Sell rating on Johnson & Johnson (NYSE: JNJ) with a price target of $80.00. Analyst Jami ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
